From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

<p>CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO&#39;s recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.</p>